Skip to content

Nordic Nanovector To Present Clinical Data from Phase I/II Trial on Betalutin™ at Upcoming American Society of Hematology (ASH) Meeting

Nordic Nanovector ASA (“Nordic Nanovector” or “the Company”) today announced that data from Betalutin’s Phase I/II trial will be presented in a poster session at the American Society of Hematology (ASH) 2014 Annual Meeting (December 6-9) in San Francisco.
The poster reports the preliminary efficacy and safety data of patients with relapsed NHL enrolled in a 3+3 dose escalation Phase I study testing 3 different dose levels of Betalutin™.
“We are looking forward to presenting the clinical results for Betalutin, the first radioimmunotherapeutic solution targeting CD-37 receptors on lymphoma cells that, thanks to its unique multi-cell kill approach, can deliver a robust clinical activity with a predictable safety profile,“ said Nordic Nanovector CEO, Luigi Costa.

The data is published on the ASH website at:

• Program: Oral and poster abstracts
• Session: 624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster II
• Title: 3094 A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin’s B Cell Lymphoma
• Date: Sunday, December 7, 2014
• Time: 6:00 PM – 8:00 PM PST
• Location: West Building, Level 1 (Moscone Center, San Francisco, CA)


Luigi Costa
Chief Executive Officer
Cell: (+41) 79 124 8601

Tone Kvåle
Chief Financial Officer
Cell: (+47) 91 51 95 76
Tel: (+47) 22 18 33 01

Source: Nordic Nanovector